BEIJING, Aug. 4, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) (“Nuokang” or the “Company”), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration (“SFDA”) review process. The Company provided the following updates on its key product candidate Kaitong, a product in-licensed from the Company’s partner, Jilin Yuhua, and Dipyridamole Aspirin, a product developed internally by Nuokang:
